Phil today announced a $60 million growth debt financing from K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm. The funding will accelerate the integration of artificial intelligence across Phil's platform and support continued customer expansion across a broad range of therapeutic areas.

Phil is a software-driven therapy deployment platform that provides pharmaceutical manufacturers with a modern alternative to traditional access, affordability, and distribution solutions. By integrating digital stakeholder experiences, patient access services, market access tools, and flexible distribution models, Phil enables manufacturers to deliver timely, affordable therapy access to patients.